DTIL PRECISION BIOSCIENCES INC
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357874 · Fiscal year ends 05/21
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY6,353.0%
TTM net income YoY53.9%
TTM EPS YoY103.6%
Revenue 3-yr CAGR-4.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-80.3%
Net margin-85.6%
FCF margin-115.0%
EBITDA margin-77.8%
Returns
ROE-112.7%
ROA-36.0%
ROIC (approx.)—
Asset turnover0.42x
Leverage & solvency
Liabilities / assets57.0%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-28.56x
Cash quality & payout
Operating cash flow / net income1.34x
Accruals ratio12.4%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $34.26M | $68.70M |
| R&D expense | $54.17M | $59.56M |
| SG&A expense | $32.24M | $35.30M |
| Operating income | -$52.15M | -$26.16M |
| Interest expense | $1.42M | $1.78M |
| Pretax income | -$45.72M | $7.17M |
| Income tax | $0 | $0 |
| Net income | -$45.72M | $7.17M |
| EBITDA | -$50.68M | -$22.76M |
| EPS (basic) | -3.56 | 1.05 |
| EPS (diluted) | -3.56 | 1.04 |
| Weighted avg. shares (diluted) | 12.83M | 6.88M |
| Balance sheet | ||
| Cash & equivalents | $110.82M | $108.47M |
| Short-term investments | $4.76M | $413,000 |
| Receivables | $0 | $229,000 |
| Current assets | $118.74M | $94.99M |
| PP&E, net | $1.43M | $3.09M |
| Intangibles | $1.17M | $622,000 |
| Total assets | $154.42M | $136.39M |
| Current liabilities | $8.91M | $14.98M |
| Total liabilities | $62.17M | $80.00M |
| Shareholders' equity | $92.25M | $56.39M |
| Shares outstanding | 24.09M | 8.20M |
| Cash flow statement | ||
| Operating cash flow | -$65.84M | -$58.45M |
| Capital expenditure | $85,000 | $250,000 |
| Free cash flow | -$65.93M | -$58.70M |
| Investing cash flow | -$634,000 | -$215,000 |
| Financing cash flow | $95.16M | $50.45M |
| Depreciation & amortization | $1.47M | $3.40M |
| Stock-based compensation | $10.19M | $12.60M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.